pamidronate has been researched along with Thalassemias in 2 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Osteoporosis is a common complication in thalassemia major (TM)." | 1.35 | Long-term effects of pamidronate in thalassemic patients with severe bone mineral density deficits. ( Cheng, FW; Chu, Y; Lee, V; Leung, TF; Leung, WK; Li, CK; Shing, MM, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Leung, TF | 1 |
| Chu, Y | 1 |
| Lee, V | 1 |
| Cheng, FW | 1 |
| Leung, WK | 1 |
| Shing, MM | 1 |
| Li, CK | 1 |
| Chatterjee, R | 1 |
| Bajoria, R | 1 |
1 trial available for pamidronate and Thalassemias
| Article | Year |
|---|---|
Osteopenia-osteoporosis syndrome in patients with thalassemia: understanding of type of bone disease and response to treatment.
Topics: Absorptiometry, Photon; Anti-Inflammatory Agents; Bone Diseases, Metabolic; Diphosphonates; Female; | 2009 |
1 other study available for pamidronate and Thalassemias
| Article | Year |
|---|---|
Long-term effects of pamidronate in thalassemic patients with severe bone mineral density deficits.
Topics: Adolescent; Adult; Blood Transfusion; Bone Density; Bone Density Conservation Agents; Calcium; Dipho | 2009 |